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2Abstract: 
Primary aldosteronism is a natural model for chronic aldosterone excess in humans and associated 
with symptoms of anxiety and depression. Cognitive deficits are inherent to the symptomatology of 
depression and anxiety disorders. Mineralocorticoid receptors and aldosterone appear to play a role in 
memory. Aldosterone was additionally supposed to be a risk factor for cognitive decline in patients 
with essential hypertension. The objective of this study was to investigate possible effects of 
chronically high aldosterone concentrations on cognitive function. A range of cognitive dimensions 
were assessed in 19 patients (9 males, 10 females; mean age 47.1 (12.5) under standardized 
treatment and several rating scales for anxiety, depression, quality of life and sleep were administered. 
Cognitive parameters were compared to standard norms from a large, healthy standardization sample. 
Patients showed increased levels of anxiety and depression without meeting diagnostic criteria for a 
disorder. Besides a numerically lower attention score, patients did not show any significant differences 
in the cognitive dimensions. Anxiety and depression were negatively correlated with quantitative 
performance in males. In females, a negative correlation between sleep disturbances and abstract 
reasoning and a positive correlation with quantitative performance were found. Our data showed no 
specific effect of chronic aldosterone in the tested cognitive parameters overall at least in younger 
patients, but they indicate sexually dimorphic regulation processes. 
Keywords: primary aldosteronism, anxiety, depression, cognition, mineralocorticoidreceptor
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31. Introduction
Patients with primary aldosteronism (PA) are thought to be a natural model for chronic aldosterone 
excess, showing significantly higher scores for depression and anxiety compared to the general 
population, with females being more affected than males 1. These patients were also found to have a 
lower quality of life (Qol) even after treatment with either a mineralocorticoid receptor (MR) antagonist 
or adrenalectomy (ADX) 2. Cognitive deficits are prevalent in depression 3, 4; however, the underlying 
pathophysiology is not fully clarified. Animal data emphasizes the importance of a balanced 
mineralocorticoid receptor (MR)/glucocorticoid receptor (GR) system for cognitive functions 5 and 
support the role of MR in memory functions. Furthermore the MR seems to be involved in emotional 
memory processes 6-8. Both the MR and aldosterone appear to be involved in the pathophysiology of 
depression and anxiety 9, 10. Subchronic treatment with aldosterone resulted in increased anxiety and 
depression-like behaviour in rats. Furthermore changes in the transcription of hippocampal genes, 
which are involved in synaptic and neuronal remodelling were found 11, 12. Similar results were 
reported for depression-like behaviour in rats after chronic treatment with a MR agonist 13. In humans, 
the MR has been shown to predict memory performance in depression (Keller et al., 2017) and 
blocking the MR in animals resulted in an impairment of the reference memory 14. After administration 
of the MR-antagonist spironolactone in healthy male controls, impaired cognitive performance in 
selective attention, delayed recall, and set shifting/mental flexibility was observed 15. In patients with 
depression, elevated aldosterone concentrations were described 16, 17, and polymorphisms in the 
angiotensin converting enzyme (ACE)-gene were reported to be associated with unipolar depression 
and hypercortisolism 18. Again hypertension itself has been found to be related to cognitive impairment 
and the development of dementia 19. Yagi et al. could additionally identify high plasma aldosterone as 
a risk factor for cognitive decline in patients with essential hypertension 20. Similar results were found 
in elder patients with essential hypertension. In these patients aldosterone was associated with lower 
blood flow and patients with higher concentrations of aldosterone were found to improve in cognitive 
functions when treating blood pressure 21. 
The aim of the present study was to specify the effects of aldosterone on cognitive functions and gain 
insight into possible pathways of cognition mediated by MR and aldosterone. 
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42. Methods
Patients
19 patients (9 males, 10 females; mean age 47.1±12.5 years; age range 18-66 years) with first 
diagnosed PA were enrolled in this study. Patients were prospectively recruited from the German Conn 
Registry. All patients had to give their written informed consent and were investigated under 
standardized antihypertensive medication according to the conn-registry-protocol (a combination of 
Verapamil, Doxazosin, and/or Urapidil), not affecting the renin-aldosterone-angiotensine-system 
(RAAS) 22. The diagnosis of PA was based on established criteria 23-25. A full examination with regard to 
basic clinical and laboratory data and several psychiatric and neuropsychological scales was 
performed.
Patients doing shift work or suffering from jetlag, or being treated with spironolactone, any psychiatric 
drugs, or hormonal therapy were excluded. Use of drugs or extensive abuse of alcohol was not 
allowed. Patients with further hormonal disturbances or known sleeping disorders were not enclosed.
The study was performed in accordance with the Declaration of Helsinki and with the "Note for 
Guidance on Good Clinical Practice for Studies on Medical Products in the European Community, July 
11, 1990". The study was approved by the ethical committee of the University of Munich.
Investigations and psychiatric assessments were performed by physicians and medically trained staff. 
The neuropsychological and psychological testing was performed by professionally trained staff at the 
Max-Planck-Institute of Psychiatry. 
 
Psychiatric scales 
Quality of life was assessed with the SF-12 questionnaire, a validated, multipurpose measure, which 
can discriminate between mental and physical aspects of quality of life 26. Reference values were set 
by the norm sample of the German population (1994) (SF-12 Manual).
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5To assess depression and anxiety, we performed the Beck Inventory of Depression (BDI), the Patient 
Health Questionnaire-9 (PHQ-9), the Hamilton Rating Scale for Depression (HAM-D), the generalized 
anxiety disorder questionnaire (GAD-7), and the Hamilton Anxiety Rating Scale (HAM-A).
The BDI, the HAM-D, and the PHQ-9 are validated measuring scales widely used for screening, 
diagnosing and specifying the severity of depression 27-29. The HAM-A and GAD-7 are instruments to 
identify and quantify the extent of anxiety 29, 30.
Reference data for the BDI was provided by Beck et al. 28. Scores of 1-10 indicate no depression, 
scores from 10-19, 20-29, and ≥30 indicate a mild, moderate, or severe depressive syndrome, 
respectively 31, 32.
Concerning the HAM-D, reference data was provided by Zimmerman et al. 33. A score of ≤8 indicates 
no depression, a mild depressive syndrome was defined for the range of 9-16 points, a moderate 
syndrome for 17-24 points, and a severe syndrome for ≥25 points 32.
Reference data for the PHQ-9 was taken by Rief et al. 34. Scores of 5, 10, 15, and 20 represented cut-points 
for mild, moderate, moderately severe and severe depression, respectively 35.
Concerning the GAD-7, normative data of the German population was defined by Lowe et al. 36. 
According to the cut-offs set by Spitzer et al. 30, scores of 5, 10, and 15 represent cut-off points for 
mild, moderate and severe anxiety. 
We used the HAM-A grading of severity suggested by Hamilton et al. 37. Ranges of 14-17, 18-24, and 
25-30 points indicate a mild, moderate, or moderate to severe level of anxiety.
Sleep quality was measured with the Pittsburgh Sleep Quality Index (PSQI). The PSQI is able to 
evaluate retrospectively the quality and patterns of sleep over a time interval of one month by 
observing seven different components which can be combined in a global score 38. Additionally we 
performed three sum scores to gain further insight to sleep quality:
 (1) ”Sleep Efficiency Sum Score” composed of  ”Sleep Duration” and ”Sleep Efficiency”; (2) 
”Perceived Sleep Quality Sum Score” composed of  ”Subjective Sleep Quality”, ”Sleep Latency”, and 
”Use of Sleeping Medication”; (3) ”Daily Disturbances Sum Score” composed of  ”Sleep Disturbances” 
and ”Daytime Dysfunction”. 
Page 5 of 21 Accepted Manuscript published as EC-19-0043.R1. Accepted for publication: 13-Mar-2019
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/21/2019 02:15:17PM
via Universitat Zurich, Universitaet Zürich and University of Zurich
6PSQI reference values from the Austrian population were used 39.
Daily fatigue was assessed with the Epworth Sleepiness Scale (ESS) 40 using German normative 
values 41. 
Neuropsychological assessment 
Neuropsychological testing was performed in the morning. Cognitive performance was evaluated using 
the d2 test for attention (d2), a validated test to rate selective attention and concentration 42. Test 
parameters for quantitative performance were total number of items processed (“GZ”) and total 
number of items minus errors, i.e., number of correctly marked items (“GZ-F”). Qualitative 
performance was represented by the percentage of errors (“F%”).
Logical memory was evaluated with the Revised Wechsler Memory Scale 43, which examines 
immediate (“Logical Memory I”) and delayed (“Logical Memory II” after 30 minutes) text reproduction. 
Executive abilities were assessed with two subtests of the Wechsler Test of Intelligence (WIE). 
“Matrices” measures abstract reasoning and fluid intelligence. The “Digit-Symbol-Test” (DST) 
assesses processing speed 44. To observe gender-dependent differences, raw data of the different 
scales were compared. Patients’ cognitive parameters were compared to norm values of the general 
population.
Hormone assays 
Blood draw for the laboratory routine and hormones cortisol and aldosterone was performed in a 
standardized procedure in the morning after resting for 10 min. Plasma aldosterone concentrations 
were measured using a commercial radioimmunoassay (DiaSorin Liasion CLIA Aldosteron ng/l). 
Plasma renin concentrations were determined using a chemiluminescence immunoassay 
(ReninLiason Diasorin Liaison Act. 4.4-64uU/ml, Italy). Cortisol was measured with a 
chemiluminescence immunoassay (Liaison Diasorin REF 313261). 
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7Statistical analysis 
Statistical analyses were carried out in SPSS Statistics for Windows, version 23 (IBM). Analysis of 
variance with age as a covariate (ANCOVA) was performed to examine sex differences. To detect 
possible associations, bivariate correlation analyses with Pearson’s coefficient were performed for 
interval-scaled variables. Canonical correlations were performed to detect possible multivariate 
correlations. To minimize the impact of missing data in the canonical correlation analysis, mean 
imputation was used. For all statistical tests, a p-value of <0.05 was set as the limit for statistical 
significance. Questionnaires that were incompletely answered or had missing values were excluded 
from further analysis.  
Results 
Basic clinical data 
All patients displayed elevated 24 hour mean blood pressure (BP) values for both systolic and diastolic 
BP (mean: 148 ± 96 mmHg). In comparison to female participants, males displayed significantly higher 
BP. The BMI was numerically higher, the waist-to-hip ratio was significantly higher in males (p=0.001). 
No statistical significance between the sexes was observed in clinical laboratory data (see Table 1). 6 
out of 10 females have been postmenopausal. Sex hormones have not been assessed. Cortisol co-
secretion was assessed in 15 patients with dexamethasone-suppression-test (DST) and salivary 
profile. Only one female patient had an elevated cortisol concentration in the salivary profile. Serum 
cortisol was within the normal ranges for all patients. 
Neuropsychological assessment 
Raw scores of male and female patients did not differ significantly in any of the neuropsychological 
parameters (see Table 1). In comparison with a norm sample, patients’ performance was average for 
most of the measures. Isolated impairments (PR≤16) could be observed in memory and attention 
measures, whereas half of the subjects showed impairment in at least one cognitive parameter. None 
of the values were far below average (PR<2) (see Figure 1). 
Psychiatric scales 
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8On average, female PA patients scored higher in all psychiatric scales in comparison with male PA 
patients. Concerning the HAM-D score, difference reached statistical significance in favor of the 
female participants (p= 0.025)  (see Table 1).
Referring to the depression-related scales, PA participants showed a mild depression severity in the 
PHQ-9. 
Regarding the BDI and the HAM-D, the PA group stayed below the cut-off for a considerable 
depression severity. But when analysed separately for gender, females showed higher scores than 
males.
In terms of anxiety-related scales, the PA group achieved higher GAD-7 means in comparison to the 
German reference data 36. Female participants showed a mild anxiety disorder, male ones stayed 
below the cutoff. 
Evaluating the HAM-A study group score, our group stayed below the cut-off set by Hamilton et al. 37. 
SF-12 
In both the physical (PCS) and the mental (MCS) SF-12 subscale, female PA participants in comparison 
to male PA participants showed lower mean values without reaching statistical significance. Referring 
to the German reference data (SF-12 Manual), the PA group explored in the present study showed 
lower mean values in both subscales.
Sleep questionnaires - ESS and PSQI 
ESS 
Male PA patients scored higher in comparison to female PA patients without reaching statistical 
significance (p= 0.427). Compared to the population-based study by Sauter et al. 41, higher scores 
were found in the PA group in the whole group. (see table 1) 
PSQI  
Female PA participants achieved higher scores in the global PSQI score as well as in all PSQI 
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9subscales, except the ”Daily Disturbances Sum Score”, the ”Sleep Duration Component Score”, and 
the ”Daytime Dysfunction Component Score” without reaching statistical significance (see Table 1 for 
p-values). Referred to the normative study by Zeitlhofer et al. 39, the PA group showed higher mean 
values in the global PSQI score as well as in all PSQI subscale scores except for the ”Use of sleeping 
medication subscale” score. (see Table1) 
Significant Correlations 
Significant correlations including the neuropsychological variables are listed in Table 2. On a 
multivariate level, no significant correlations appeared. Observing bivariate associations, the total 
number of items processed (“GZ”) showed negative associations with depression- as well as anxiety-
related scales. These negative associations were partly present in the male PA subgroup without 
equivalent in the female PA subgroup. Additionally, the percentage of errors (“F%”) correlated 
negatively with the Physical Health Composite Scale score (PCS) of the SF-12  in the male PA group. 
Both male and female PA participants showed a negative correlation between the PSQI and 
neuropsychological parameters, the negative association including the ESS was limited to the male 
PA group. 
Observing hormonal associations, neuropsychological parameters correlated negatively with the 
plasma renin concentration in the male PA group  and positively with serum aldosterone levels in the 
female PA group.
4. Discussion
The aim of our study was to shed light on the effects of aldosterone and MR on attention and memory 
functions in patients with PA treated with standardised medication. Although patients with a manifest 
psychiatric disorder according to DSM-IV were excluded, anxiety and depressive symptoms were 
elevated and Qol was reduced with higher affection in female patients as described in previous studies 
1, 2. Sleep quality measured by PSQI was subjectively impaired in PA. All patients scored within the 
norm values of the general population in all tested cognitive dimensions (attention, logical memory, 
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executive functions). No significant differences between male and female patients were detected. 
However, half of the participants showed at least impairment in memory and attention measures.
Overall, a significant negative correlation for quantitative performance, measured with GZ and 
depression and anxiety was found, gender-specific analyses revealed that this effect was only 
significant in males. In males experienced anxiety and depression as well as sleep disturbances and 
daytime sleepiness are significantly negative correlated with quantitative performance, meaning a 
deceleration in their processing speed. Qualitative performance was negatively correlated with 
physical subscale in males. The cognitive profile of male patients was otherwise neither comparable to 
patients with anxiety disorders, for whom impairments in attention, memory and emotional intelligence 
have been described (Chutko LS et al. 2014, Castaneda AE et al 2007), nor patients with depression, 
for whom impairments in attention, executive functions and memory have been reported 45. In females, 
GZ was positively correlated to aldosterone. Although the number of subjects is small, this finding is 
not in line with the assumption of aldosterone being a risk factor for cognitive impairment 20, 21. Only in 
females subjective sleep quality in the PSQI had a negative influence on executive functions measure 
by abstract reasoning. 
The absence of specific patterns in cognitive impairment could be explained by the fact, that patients 
did not reach DSM-IV or ICD-10 criteria to be diagnosed with a depression or anxiety disorder, but 
only showed elevated levels of symptoms compared with the general population. 
Neuropsychological dimensions were not systematically associated with any of the physical 
parameters such as blood pressure or aldosterone. There are hints that aldosterone is associated with 
lower cerebrovascular function in hypertension 20, 21 and the association between early stage 
Alzheimer's disease and plasma renin-angiotensin-system aminopeptidase activities could be gender 
specific 46. We found significant correlations between aldosterone and GZ in females and plasma renin 
and DST in males, but further investigation is warranted. Differences to other studies might be 
explained by the younger age of our patients in contrast to patients of the other studies.    
Several studies investigated the role of the MR, the main target of aldosterone, in memory processes. 
These studies suggest MR to be mainly involved in fear memory and emotional arousal as well as the 
processing of this information 47. In our sample of patients with PA, chronic exposure to high 
concentrations of aldosterone did not show marked effects on cognition. This is in contrast to previous 
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finding in healthy male subjects, where acute blocking of the MR with spironolactone resulted in 
consecutive impairment in several cognitive dimensions 15. These contrasting findings could be due to 
different underlying mechanisms associated with chronic exposure to aldosterone versus acute 
blockade with a MR antagonist. Sex differences in memory functions related to MR function have been 
described in animal data 48 and sexually dimorphic regulation of the MR and gender specific effects of 
aldosterone are at least described for other tissues 49, 50.        
Chronic aldosterone excess seems not to influence immediate and delayed memory, cognitive and 
quantitave performance, abstract reasoning and the processing speed in our younger sample 
systematically. Emotional memory processes should be issue of further investigations. Sexually 
dimorphic regulation processes in effects of aldosterone and MR mediated processes are indicated by 
these data, because aldosterone was significantly associated with quantitative performance in women. 
This study is limited by a small number of patients. Due to the small group of female patients, no 
analytical discrimination in pre- and post-menopausal status was done. A comparison with 
hypertensive patients would be interesting in future studies. Strengths of this study is an investigation 
under standardized conditions and a very good characterisation that enabled to assess possible 
interfering factors like fatigue or sleeping disturbances. 
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Figure 1. Neuropsychological assessment
Indication of individual data for males and females according to their neuropsychological performance
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Tables
Table 1. Clinical data of the patients studied
Whole Group PA Men PA Women p-
value
Number N 19 9 10 -
Age (in y) 47.1 (12.5) 48.4 (10.9) 45.9 (14.3) -
Mean time until first diagnose (months) 112.8 (101.8) 113.3 (65.3) 112.5 (130.3) -
Mean 24h systolic BP in mmHg 148 (15) 154 (18) 143 (8) 0.124
Mean 24h diastolic BP in mmHg 96 (9) 100 (8) 91 (8) 0.023
Mean systolic BP at daytime in mmHg 150 (16) 155 (20) 145 (11) 0.217
Mean diastolic BP at daytime in mmHg 97 (10) 101 (10) 92 (8) 0.114
Mean systolic BP at night in mmHg 141 (14) 150 (13) 131 (6) 0.002
Mean diastolic BP at night in mmHg 89 (10) 96 (5) 81 (9) <0.001
Waist-To-Hip Ratio 0.9 (0.1) 0.9 (0.1) 0.8 (0.1) 0.001
Body mass index in kg/m2 27.2 (3.9) 28.8 (3.6) 25.7 (3.8) 0.104
Serum sodium in mmol/l (135 – 150 
mmol/l)
141 (3) 141 (3) 140 (3) 0.765
Serum potassium (3.5 – 5.0 mmol/l) 3.5 (0.5) 3.4 (0.4) 3.6 (0.6) 0.317
Serum cortisol (1.8 bis 24.0 µg/dl) 13 (4) 14 (4) 12 (4) 0.508
Serum aldosterone (40 – 310 ng/l) 231 (184) 200 (138) 258 (222) 0.534
Plasma renin concentration (8 – 99 
µU/ml)
4.4 (3.8) 4.6 (4.9) 4.1 (2.5) 0.702
Aldosterone / renin ratio (<20 ng/l/mU/l) 79.8 (75.9) 84.2 (95.9) 75.8 (57.5) 0.889
GZ (raw data) 404 (48) 420 (42) 389 (51) 0.222
GZ 29.6 (18.2) 35.4 (19.5) 23.9 (16.0)
GZ-F (raw data) 390 (46) 404 (43) 377 (49) 0.277
GZ-F 33.4 (19.8) 38.5 (23.1) 28.4 (15.9)
F% (raw data) 3.8 (2.9) 4.5 (2.2) 3.0 (3.4) 0.276
F% 64.6 (23.6) 56.8 (18.2) 72.5 (26.8)
Logical Memory I (raw data) 27.9 (6.3) 28.4 (5.7) 27.5 (7.2) 0.813
Logical Memory I 52.7 (32.2) 57.3 (28.4) 48.1 (36.9)
Logical Memory II (raw data) 25.1 (6.2) 25.3 (6.0) 24.9 (6.8) 0.926
Logical Memory II 52.3 (30.3) 54.8 (24.9) 49.8 (36.6)
Matrices (WIE) (raw data) 17.2 (6.0) 18.8 (6.2) 15.6 (5.7) 0.190
Matrices (WIE) 59.5 (28.7) 66.0 (28.4) 53.0  (29.4)
DST (WIE) (raw data) 74.1 (10.9) 74.9 (9.1) 73.3 (13.2) 0.800
DST (WIE) 62.0 (25.6) 60.4 (28.4) 63.6 (24.2)
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PHQ-9
Reference value (RV) (cut-off: <5)
6.5 (5.3)
3.56 (4.08)
5.8 (5.8) 7.4 (4.9) 0.525
HAM-D
RV (cut-off: ≤8)
5.8 (5.5)
3.2 (3.2)
3.2 (2.7)
3.3 (3.3)
8.4 (6.4)
3.1 (3.2)
0.025
BDI
(cut-off: <10)
4.2 (6.2) 2.1 (3.4) 6.6 (7.9) 0.118
GAD-7
RV (cut-off: <5)
5.6 (5.6)
2.95 (3.41)
3.6 (3.5)
2.66 (3.24)
7.9 (6.8)
3.20 (3.52)
0.076
HAM-A 
RV (cut-off: <14)
7.4 (7.1) 4.8 (4.9) 10.1 (8.1) 0.153
SF-12; PCS
RV
45.3 (12.1) 46.8 (11.7)
50.2 (8.68)
43.0 (13.4)
47.9 (9.74)
0.416
SF-12; MCS
RV
50.8 (9.1) 51.0 (7.5)
53.25 (7.57)
50.6 (11.9)
51.30 (8.41)
0.936
ESS
RV
8.1 (4.7)
6.6 (3.5)
8.8 (4.6)
6.9 (3.3)
7.4 (4.9)
6.2 (3.7)
0.427
PSQI- Global Score
RV
6.4 (4.1)
4.55 (3.71)
6.1 (4.7)
-
6.7 (3.8)
-
0.675
PSQI- Subjective Sleep Quality
RV
1.4 (0.7)
0.75 (0.78)
1.3 (0.7) 1.6 (0.8) 0.462
PSQI- Sleep Latency
RV
1.3 (1.0)
0.88 (0.85)
1.00 (1.0) 1.6 (0.9) 0.141
PSQI- Sleep Duration
RV
0.9 (0.9)
0.74 (0.71)
1.00 (1.0) 0.9 (1.1) 0.907
PSQI- Habitual Sleep Efficiency
RV
0.5 (0.9)
0.31 (0.71)
0.3 (1.0) 0.7 (0.8) 0.411
PSQI- Sleep Disturbances
RV
1.3 (0.7)
0.83 (0.99)
1.2 (0.7) 1.3 (0.8) 0.714
PSQI- Use of Sleeping Medication
RV
0.0 (0.0)
0.23 (0.68)
0.0 (0.0) 0.0 (0.0) -
PSQI- Daytime Dysfunction
RV
1.0 (0.9)
0.82 (0.76)
1.2 (1.2) 0.7 (0.5) 0.359
PSQI- Sleep Effiency Sum Score 1.4 (1.7) 1.3 (1.9) 1.6 (1.6) 0.719
PSQI- Perceived Sleep Quality Sum 
Score
2.7 (1.5) 2.3 (1.5) 3.1 (1.6) 0.194
PSQI- Daily Disturbances Sum Score 2.3 (1.5) 2.4 (1.5) 2.0 (1.2) 0.668
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Table 2. Significant Correlations 
Group Parameters Correlation 
Coefficient
Sig.
GZ PHQ-9 -0.552 0.033
GZ GAD-7 -0.679 0.005
GZ HAM-A -0.572 0.021
Whole 
Group
Neuropsychological assessment - Psychiatric, Quality of life and 
Sleep scales
GZ HAM-D -0.528 0.036
GZ PHQ-9 -0.799 0.017
GZ GAD-7 -0.840 0.009
GZ ESS -0.728 0.040
GZ PSQI -0.774 0.024
Neuropsychological assessment - Psychiatric, Quality of life and 
Sleep scales
F% SF-12 (PCS) -0.732 0.039
PA Men 
Neuropsychological assessment - Hormones DST (WIE) Plasma renin -0.878 0.004
Neuropsychological assessment - Psychiatric, Quality of life and 
Sleep scales
Matrices (WIE) PSQI -0.918 0.010
PA Women 
Neuropsychological assessment - Hormones GZ
Serum 
aldosterone 
+0.729 0.040
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Figures 
Figure 1. Neuropsychological assessment  
Indication of individual data for males and females according to their neuropsychological performance 
    M M M M M M M M F F F F F F F F           
  GZ                                            
  GZ F                                     far above average (PR≥98)   
  F%                                      above average (PR=84-98)   
  Memory 1                                      average (PR=16-84)   
  Memory 2                                     below average (PR=2-16)   
  Matrices                                      far below average (PR≤2)   
  ZST                                            
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